Teva and Samsung Bioepis Launch Epysqli (Biosimilar, Soliris) in the US

Shots:Teva & Samsung Bioepis have launched Epysqli, a biosimilar version of Soliris (eculizumab) in the US to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) & generalized myasthenia gravis(gMG) in AchR antibody-positive adultsEpysqli was approved by the US FDA in Jul 2024 for PNH & aHUS, with a label expansion to gMG in…

ByRidhi RastogiApril 8, 2025

News

Samsung Bioepis Reports the US FDA’s Approval of Epysqli (Biosimilar, Soliris)

Shots: The US FDA has granted approval to the company’s BLA of Epysqli (eculizumab-aagh), a biosimilar version of Soliris (eculizumab) Approval was supported by data from the P-I trial depicting similar PK/PD, safety, tolerability & immunogenicity profiles among healthy subjects and the P-III trial showing comparable efficacy, safety, PK & immunogenicity in PNH patients b/w Epysqli vs Soliris …

ByDipanshu DixitJuly 22, 2024

TOP 20

Top 20 Monoclonal Antibodies Based on 2022 Total Revenue

Shots:Monoclonal antibodies are transforming therapeutics through their highly efficient targeting mechanisms. There is a wide range of uses for monoclonal antibodies, including diagnosis, therapy, and researchIn 2021, the monoclonal antibody therapy market size was valued at $178.5B and is envisioned to reach $451.89B by 2028, displaying a CAGR of 14.1%. Humira was the…

ByPrince GiriSeptember 26, 2023

Teva and Samsung Bioepis Launch Epysqli (Biosimilar, Soliris) in the US

Samsung Bioepis Reports the US FDA’s Approval of Epysqli (Biosimilar, Soliris)

Top 20 Monoclonal Antibodies Based on 2022 Total Revenue

Contact US

OUR INFORMATION

FOLLOW US